Emerging Treatment Considerations in HCC: An Expert Case-Based Discussion

Expert oncologists Tanios Bekaii-Saab, MD; Anthony El-Khoueiry, MD; Pierre Gholam, MD; Arndt Vogel, MD; and Mark Yarchoan, MD, review data from ASCO 2022 and discuss updates in the management of HCC.

EP. 1: Patient Profile 1: Resection for Early/Intermediate Stage HCC

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

EP. 2: Early-Stage HCC: Role of Adjuvant Therapy

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

EP. 3: Early-Stage HCC: What is the Role of Neoadjuvant Therapy?

July 6th 2022

Expert oncologists consider when it would be appropriate to use neoadjuvant therapy for early-/intermediate-stage hepatocellular carcinoma.

EP. 4: Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

July 6th 2022

Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC Locoregional Treatment Strategies in Early-/Intermediate-Stage HCC

EP. 5: Selection and Use of Systemic Therapy in Intermediate Stage HCC

July 13th 2022

Panelists consider the role of systemic therapy in patients with intermediate-stage HCC who are ineligible for locoregional therapy.

EP. 6: Management of HCC: Advances in Biomarkers and Screening

July 13th 2022

A brief review of predictive and prognostic biomarker needs in hepatocellular carcinoma, followed by discussion on screening and detection.

EP. 7: Patient Profile 2: Frontline Therapy for Advanced HCC

July 20th 2022

Centering discussion on a patient with advanced-stage HCC, expert panelists discuss the frontline use of atezolizumab + bevacizumab as a standard of care.

EP. 8: HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

July 20th 2022

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

EP. 9: Real-World Selection of Frontline Combination Therapy for Advanced HCC

July 27th 2022

Taking into account respective data from IMbrave150 and HIMALAYA, experts consider how they might select frontline therapy for advanced HCC.

EP. 10: Role of Hepatitis Status in Selecting Therapy for HCC

July 27th 2022

Expert panelists briefly review how a patient’s hepatitis status may influence treatment selection for advanced hepatocellular carcinoma.

EP. 11: Frontline Lenvatinib versus Sorafenib Treatment in Advanced HCC

August 3rd 2022

Comprehensive insight on the selection and use of frontline tyrosine kinase inhibitors for patients with advanced hepatocellular carcinoma.

EP. 12: Frontline Therapy for Advanced HCC: Novel Combination Strategies

August 3rd 2022

Before closing out their discussion on frontline therapy for advanced HCC, expert panelists review other novel combinations under investigation.

EP. 13: Patient Profile 3: Second-Line Therapy for Advanced HCC

August 10th 2022

Centering discussion on a patient with advanced HCC, expert oncologists consider which agents they would use in the second line following lenvatinib failure.

EP. 14: Selecting Therapy for Advanced HCC Following TKI Failure

August 10th 2022

Shared insight on which factors help to inform selection of second-line therapy for patients with advanced HCC following lenvatinib failure.

EP. 15: Selecting Therapy for Advanced HCC Following Atezo-Bev Failure

August 17th 2022

Expert panelists consider which therapy they would use following failure of atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

EP. 16: Later-Line IO Therapy for Advanced Hepatocellular Carcinoma

August 17th 2022

Comprehensive insight on later-line immunotherapy and combination strategies available for patients with advanced hepatocellular carcinoma.

EP. 17: The Evolving Treatment Landscape of HCC

August 24th 2022

Closing out their discussion on hepatocellular carcinoma, expert panelists consider future directions in care.